Effect of alirocumab on coronary plaque stratified by atherothrombotic risk
Among AMI patients, the addition of alirocumab to high-intensity statin therapy resulted in greater coronary plaque regression and lipid burden reduction in patients not at VHR. Further investigation is needed to clarify the impact of atherothrombotic risks on plaque regression and subsequent risk reduction in different patient subsets.
Authors
- Tadashi Itagaki (ORCID: https://orcid.org/0000-0003-0176-8380)
- Jonas Häner (ORCID: https://orcid.org/0000-0002-1420-8967)
- David Spirk
- Joost Daemen (ORCID: https://orcid.org/0000-0001-8628-1410)
- Juan F. Iglesias (ORCID: https://orcid.org/0000-0002-1669-6036)
- Robert‐Jan van Geuns (ORCID: https://orcid.org/0000-0003-2943-5932)
- Lorenz Räber (ORCID: https://orcid.org/0000-0003-0824-3026)
- Tatsuhiko Otsuka (ORCID: https://orcid.org/0000-0001-7737-0374)
- Hiroki Shibutani (ORCID: https://orcid.org/0000-0002-3593-3981)
- Thomas Engstrøm (ORCID: https://orcid.org/0000-0001-5436-9194)
- Iréne Lang (ORCID: https://orcid.org/0000-0003-0485-2692)
- Ryota Kakizaki (ORCID: https://orcid.org/0009-0009-1133-2864)
- Sarah Bär (ORCID: https://orcid.org/0000-0003-0045-6596)
- Sylvain Losdat (ORCID: https://orcid.org/0000-0001-7673-4877)
- Konstantinos C. Koskinas (ORCID: https://orcid.org/0000-0002-5589-7762)
- Yasushi Ueki (ORCID: https://orcid.org/0000-0003-4630-9815)
Institutions
- University of Bern (CH)
- Radboud University Nijmegen (NL)
- University Hospital of Bern (CH)
- Erasmus MC (NL)
- Copenhagen University Hospital (DK)
- Rigshospitalet (DK)
- Radboud University Medical Center (NL)
- University Hospital of Geneva (CH)
- Medical University of Vienna (AT)
Publication Details
- Journal
- Atherosclerosis
- Published
- 2025-11-24
- DOI
- https://doi.org/10.1016/j.atherosclerosis.2025.120588
- Citations
- 1
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 2.01